Skin & Allergy News - Tetracycline Derivative Induces Lupus
A new angiogenesis agent being tested in a phase I cancer trial induced phototoxicity and systemic lupus erythematosus in 3 of 35 patients.
The compound, 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (COL-3), is the second tetracycline derivative to be associated with drug-induced lupus, reported Dr. Jayashri V. Ghate and colleagues at the National Cancer Institute (Arch. Dermatol. 137[4]:471-74, 2001). Minocycline has also been reported to induce lupus, as have other compounds unrelated to tetracycline, including procainamide, hydralazine, and antithyroid drugs.
Related Results
TetracyclinesTetracyclinesNew Uses for an Old Drug: Rebirth of the TetracyclinesTetracycline diffusion through bacterial cellulose—polyvinyl alcohol…TETRACYCLINE FIBRE APPROVED IN EUROPE
The patients, all three of whom had metastatic cancer (two had prostate cancer and one had colon cancer), experienced phototoxic skin eruptions despite using sunblock and avoiding the sun. All tested positive for antinuclear antibodies, and two had elevated antihistone antibody levels. All experienced fever, and two had arthralgia, one with joint swelling.
The symptoms cleared within a few weeks of discontinuing COL-3 in two of the patients, but have been recurrent in the third. No new patients are being enrolled in the clinical trial at this time, the investigators said.
COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
